# Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis

> **NCT04088721** · PHASE1,PHASE2 · COMPLETED · sponsor: **Advagene Biopharma Co. Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** AD17002
- **OTHER:** Formulation Buffer

## Key facts

- **NCT ID:** NCT04088721
- **Lead sponsor:** Advagene Biopharma Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2020-07-30
- **Final completion:** 2020-12-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04088721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04088721, "Tolerability and Potential Efficacy of AD17002 in Subjects With Allergic Rhinitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04088721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*